InspireMD, Inc.NSPREarnings & Financial Report
InspireMD Inc. is a global medical device company specializing in innovative interventional cardiology and neurovascular solutions. Its flagship MGuard embolic protection stent line is engineered to reduce complications during vascular procedures, serving clinical customers across North America, Europe, and key Asia-Pacific markets, with a core focus on improving patient outcomes for acute coronary syndrome and stroke care.
Revenue
$1.8M
Gross Profit
$414.0K
Operating Profit
$-8.5M
Net Profit
$-7.9M
Gross Margin
22.9%
Operating Margin
-467.5%
Net Margin
-435.9%
YoY Growth
16.3%
EPS
$-0.16
InspireMD, Inc. Q3 FY2024 Financial Summary
InspireMD, Inc. reported revenue of $1.8M (up 16.3% YoY) for Q3 FY2024, with a net profit of $-7.9M (down 52.4% YoY) (-435.9% margin). Cost of goods sold was $1.4M, operating expenses totaled $8.9M.
Key Financial Metrics
| Total Revenue | $1.8M |
|---|---|
| Net Profit | $-7.9M |
| Gross Margin | 22.9% |
| Operating Margin | -467.5% |
| Report Period | Q3 FY2024 |
InspireMD, Inc. Annual Revenue by Year
InspireMD, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $9.0M).
| Year | Annual Revenue |
|---|---|
| 2025 | $9.0M |
| 2024 | $7.0M |
| 2023 | $6.2M |
| 2022 | $5.2M |
InspireMD, Inc. Quarterly Revenue & Net Profit History
InspireMD, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $3.1M | +61.6% | N/A | N/A |
| Q3 FY2025 | $2.5M | +39.4% | $-12.7M | -503.7% |
| Q2 FY2025 | $1.8M | +2.2% | $-13.2M | -739.7% |
| Q1 FY2025 | $1.5M | +1.2% | $-11.2M | -730.3% |
| Q4 FY2024 | $1.9M | +10.7% | N/A | N/A |
| Q3 FY2024 | $1.8M | +16.3% | $-7.9M | -435.9% |
| Q2 FY2024 | $1.7M | +5.5% | $-7.9M | -454.8% |
| Q1 FY2024 | $1.5M | +22.0% | $-7.0M | -465.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $1.7M | $1.8M | $1.9M | $1.5M | $1.8M | $2.5M | $3.1M |
| YoY Growth | 22.0% | 5.5% | 16.3% | 10.7% | 1.2% | 2.2% | 39.4% | 61.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $42.0M | $55.7M | $50.5M | $46.8M | $38.7M | $33.3M | $78.5M | $69.4M |
| Liabilities | $6.9M | $8.9M | $9.1M | $10.7M | $10.3M | $13.1M | $14.4M | $14.2M |
| Equity | $35.1M | $46.8M | $41.4M | $36.1M | $28.3M | $20.2M | $64.1M | $55.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-5.1M | $-4.4M | $-5.7M | $-6.8M | $-8.8M | $-8.3M | $-8.6M | $-9.3M |